Spots Global Cancer Trial Database for Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases
Official Title: The International Liver Tumor Group RAS-trial Radiofrequency Ablation Versus Stereotactic Body Radiation Therapy for Colorectal Liver Metastases: A Randomized Trial
Study ID: NCT01233544
Interventions
Study Description
Brief Summary: This randomized clinical phase III trial is testing the efficacy of radiofrequency ablation (RFA) and stereotactic body radiotherapy (SBRT) in the treatment of colorectal carcinoma liver metastases. Primary end point is local progression free survival.
Detailed Description: Patients with 1-4 inoperable colorectal liver metastases, no more 4 cm in diameter are randomized to either RFA or SBRT. Primary end point i local progression free survival. Chemotherapy is allowed before and after study treatment.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Aarhus University Hospital, Aarhus C, , Denmark
Karolinska Institute, Huddinge, Stockholm, , Sweden
Contact Details
Name: Morten Høyer, MD PhD
Affiliation: Aarhus University Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
